Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma

BACKGROUND: Renal cell carcinoma (RCC) is a highly vascular tumor and patients with low risk metastatic RCC of clear-cell histological sub-type (mccRCC) are treated with tyrosine-kinase inhibitors (TKIs), sunitinib, as the first-line of treatment. Unfortunately, TKI resistance eventually develops, a...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Costa, Ninadh M., Lowerison, Matthew R., Raven, Peter A., Tan, Zheng, Roberts, Morgan E., Shrestha, Raunak, Urban, Matthew W., Monjaras-Avila, Cesar U., Oo, Htoo Zarni, Hurtado-Coll, Antonio, Chavez-Munoz, Claudia, So, Alan I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011538/
https://www.ncbi.nlm.nih.gov/pubmed/32041631
http://dx.doi.org/10.1186/s13046-020-1527-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011538/
https://www.ncbi.nlm.nih.gov/pubmed/32041631
http://dx.doi.org/10.1186/s13046-020-1527-y

Ejemplares similares